DOI:
10.1055/s-00034922
Arthritis und Rheuma
LinksClose Window
References
Mease P, Kellner H, Morita A. et al.
Efficacy and Safety Results from a Phase 2 Trial of Risankizumab, a Selective IL-23p19 Inhibitor, in Patients with Active Psoriatic Arthritis [abstract].
Arthritis Rheum. 2017
69. (suppl 10).
Access:
We do not assume any responsibility for the contents of the web pages of other providers.